Clinical Trials Logo

Hearing Loss, Sudden clinical trials

View clinical trials related to Hearing Loss, Sudden.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06467526 Not yet recruiting - Sudden Hearing Loss Clinical Trials

Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Sudden sensorineural hearing loss (SSNHL) is diagnosed when there's a sudden drop in hearing of at least 30 decibels across three consecutive frequencies, emerging within up to 72 hours. In clinical settings, steroids are the predominant treatment for SSNHL. However, the outcomes for patients undergoing steroid therapy for SSNHL can differ substantially. Moreover, a systematic review of randomized clinical trials has found no conclusive evidence pinpointing an effective treatment for SSNHL. Hydroxychloroquine, a derivative of chloroquine, is a medication that has gained attention for its potential role in modulating the immune response. We aim to see if hydroxychloroquine could augment hearing recovery in SSNHL under steroid treatment and to evaluate the safety of hydroxychloroquine in the treatment of SSNHL patients. We plan to enroll 80 SSNHL patients who received oral steroid therapy and randomize them into an experimental group (hydroxychloroquine with prednisolone, 40 patients) and a control group (prednisolone, 40 patients). The primary endpoint will be the change in pure tone audiogram (PTA) in the affected ear from screening until 3 months. The secondary endpoints will be the change in word recognition score and the change in bilateral tinnitus severity after treatment. Any side effects will be recorded to ensure the safety of this clinical trial.

NCT ID: NCT06437054 Not yet recruiting - Clinical trials for Hearing Loss, Sensorineural

Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss

Start date: February 15, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a prospective, randomized pilot study. To verify an efficacy/safety of the mixed drug injectable delivery vehicle for treating intractable hearing loss. Hearing test, endoscopy of tympanic membrane and CT scans will be conducted after intratympanic treatment for evaluation.

NCT ID: NCT06365775 Not yet recruiting - Clinical trials for Hearing Loss, Sensorineural

Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss

Start date: April 23, 2024
Phase:
Study type: Observational

The goal of this observational study is to describe the multi-omics characteristics and to learn about the prognostic factors in patients with idiopathic sudden sensorineural hearing loss (SSNHL). The main problems it aims to deal with are: - if there is a difference in data of exome and targeted sequencing among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls - if there is a difference in the parameter of MRI among patients with SSNHL affecting bilateral and unilateral sides, and healthy controls - to find out which factor from multi-omics data relates to outcomes of SSNHL - to develop the best prognostics model based on the multi-omics data. Participants will be received audiological tests, blood specimen collection and radiological examination. Researchers will explore the relationship between the multi-omics data and the prognosis and develop the predictive model.

NCT ID: NCT05786378 Not yet recruiting - Hearing Loss Clinical Trials

Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.

Start date: June 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

Assessment of the efficacy of Intratympanic platelet rich plasma injection for treatment of idiopathic suden sensorineural hearing loss

NCT ID: NCT04449848 Not yet recruiting - Sudden Hearing Loss Clinical Trials

The Effect of Patient's Position After Intra-tympanic Injection on the Amount of Fluid in the Middle Ear

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

During the regular protocol of Intra-tympanic injections of Dexamethasone to the middle ear due to Sudden Sensorineural Hearing Loss, the patients will be sitted once after the injection instead of lying down. They will be then asked to rate their taste as a reference to the amount of fluid leaking to the throat through the eustachian tube.

NCT ID: NCT04384640 Not yet recruiting - Sudden Hearing Loss Clinical Trials

The Effect of Patient's Position After Intra-tympanic Injection

Start date: July 1, 2020
Phase:
Study type: Observational

The effect of the patient's head on the leakage of steroids from the middle ear to the throat will be studied. The patients will be seated after one of the intra tympanic injections that are routonely performed due to Sudden Sensorineural Hearin Loss (SNHL). The patients will be asked if they taste the steroids in their throats.

NCT ID: NCT04129983 Not yet recruiting - Clinical trials for Hearing Loss, Sudden

Treatment of Sudden Deafness With Prednisone+Hyperbaric Oxygen and Prednisone+Somatosensory Stimulation

Start date: June 2020
Phase: N/A
Study type: Interventional

To study the effective treatment of sudden deafness by giving prednisone, hyperbaric oxygen and somatosensory stimulation to sudden deafness patients.

NCT ID: NCT04129697 Not yet recruiting - Clinical trials for Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid

Intratympanic Steroids for Sudden Hearing Loss

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

For patients with sudden hearing loss, the initial treatment is not usually effective. We use Dexamethasone or Methylprednisolone to be an Intratympanic steroid administration as a salvage treatment. An randomized, double-blind, multi-center study is designed to find the difference between Dexamethasone or Methylprednisolone.

NCT ID: NCT03974867 Not yet recruiting - Sudden Hearing Loss Clinical Trials

Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids

Start date: July 2019
Phase: N/A
Study type: Interventional

Idiopathic sudden sensorineural hearing loss (ISSNHL) is a complicated hearing impairment with unclear etiology and unsatisfying treatment effects. Vestibular dysfunction like vertigo has been considered as a risk factor of profound hearing loss and poor prognosis in ISSNHL. Glucocorticoids, administered through oral or intratympanic way, is currently a regular and standard treatment for ISSNHL based on hearing outcome. However, little investigations have been conducted on recovery process and treatment effects of glucocorticoids on vestibular dysfunctions of ISSNHL. This study aims to evaluate the recovery pattern and possible process of vestibular system in ISSNHL with vestibular dysfunction, and to compare the efficacy of oral or intratympanic glucocorticoids in these participants. A randomized, outcome assessor- and statistical analyst-blinded, controlled, clinical trial will be carried out. 72 patients complaining of vestibular dysfunction appearing as vertigo, dizziness, imbalance or lateropulsion with ISSNHL will be recruited and randomized into two arms of oral or intratympanic glucocorticoids therapy in 1:1 allocation. The primary outcomes will be subjective feelings evaluated by duration of vestibular dysfunction symptoms, dizziness-related handicap, visual analogue scale for vertigo, and objective vestibular function tests results assessed by sensory organization test, caloric test, video head impulse test and vestibular evoked myogenic potentials. Assessment will be performed at baseline and at 1, 2, 4, and 8 weeks post-randomization.

NCT ID: NCT03706183 Not yet recruiting - Ischemia Clinical Trials

Ischemia- Modified Albumin Levels in the Sudden Hearing Loss

IMA
Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

To evaluate ischemia-modified albumin levels in these patients to investigate the presence of ischemia in patients presenting with sudden hearing loss.